Analyst Price Target is $8.33
▲ +166.24% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for CureVac in the last 3 months. The average price target is $8.33, with a high forecast of $13.00 and a low forecast of $4.00. The average price target represents a 166.24% upside from the last price of $3.13.
Current Consensus is
Hold
The current consensus among 5 polled investment analysts is to hold stock in CureVac. This Hold consensus rating has held steady for over two years.
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company also develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Read More